Microorganisms, also called microbes, are the collective name of all tiny organisms that are invisible to the naked eye. Harmful microorganisms are called pathogenic microorganisms which can cause diseases. Antimicrobial drugs refer to any substance that inhibits and kills pathogenic microorganisms and are used to treat infectious diseases. They can interfere with the life cycle of microorganisms and thereby impeding their growth and reproduction. Antimicrobial agents can be classified into antibiotics or antibacterial drugs, antifungal drugs, antiviral drugs, antiparasitic drugs and antiprotozoal drugs according to the microorganisms they act primarily against.
Diseases caused by pathogenic microorganisms are called infectious diseases. Common infectious diseases are hepatitis B, hepatitis C, tuberculosis, malaria, influenza, HIV, etc. Infectious diseases are infectious and epidemic, and some of them are also seasonal or endemic. These characteristics make infectious diseases account for a substantial proportion of deaths worldwide. The introduction into clinical use of antimicrobial drugs since the 1940s has once led to a rapid decline in the mortality rate of infectious diseases. However, the treatment of many infections has been challenged by the increasing resistance of pathogens to antimicrobial drugs. This correlation clearly demonstrates the importance of antimicrobial drugs in the control of infectious diseases. Therefore, there is an urgent need to develop new antimicrobial drugs to solve the problem of drug resistance.
Figure 1. Time From Antibiotic Approval or Introduction to Detection of Resistance in Clinical Samples. (Marston, H. D., et al., 2016)
The high cost of bringing a new drug to market includes the cost of drugs that cannot pass the development phase due to lack of efficacy or safety. It is reasonable to reduce the cost of drug development by more accurate selection of drugs that may achieve the goal of proving safety and efficacy, and by stopping early in development of unsafe and ineffective drugs as soon as possible.
Creative Biolabs provides powerful risk-based preclinical data verification services for antimicrobial drug research and development to deal with data reproducibility crisis which is a big obstacle for drug research and development and may lead to failure and high risk of investment. We have extensive experience in different kinds of antimicrobial drugs and different disease areas with a focus on target validation, hit validation, lead validation, safety assessment and efficacy evaluation.
Creative Biolabs is a global specialized contract research organization offering comprehensive and high-quality services to support antimicrobial drug research and development projects of our clients. Comprehensive cell lines and animal models, especially disease models, are available at Creative Biolabs to support both in vitro and in vivo pharmaceutical studies. Both the safety and the efficacy of your drug candidates will be fully assessed.
With our experienced experts and advanced technology, the key data in your project will be verified to confirm the accuracy and repeatability of preclinical experiments. The development potential of the drug candidate will be judged as soon as possible. Creative Biolabs provides reliable project feasibility assessment to help you make reasonable decisions so as to reduce investment risk and speed up the project.
Creative Biolabs provides customized services according to your specific needs in a timely and cost-effective manner. Please feel free to contact us for more detailed information and let us know how we can help you. We will do our best to serve your interests.
Marston, H. D., et al., 2016. Antimicrobial resistance. Jama, 316(11), pp. 1193-1204.